Here is a link to Aciont's web site's pdf file that illustrates the Visulex system; the same figure is in the referenced DDT article. Apparently, the applicator is inserted under the lower eyelid during an office visit, electric current is run for 15-20 minutes, resulting in the drug being transferred from the applicator into the eye.
The drug being administered would need to be able to be administered in a charged state and be able to permeate outer eye membranes with electrical assistance.
The frequent of office visits would probably be similar to the frequency of eye injections required.
The Visulex drug delivery technology is a recent development for Aciont and they are targeting the need to eliminate eye injections in treating AMD and other BOTE diseases.
Visulex seems to be a technology that AMD competitors will "keep an eye on" and appears to be Aciont's major focus at the moment.
Market Data 
Markets 
AI
